Although clinical data using MYC status as a biomarker to guide TOP1 inhibitor therapy are still limited, preclinical evidence supports that MYC‐overexpressing tumours display increased sensitivity to TOP1 inhibitors. This evidence concerns the gene MYC and neoplasm.